Recruitment closed NOVEMBER 2018
Trial Status: Complete
This pre-operative window of opportunity study will use functional imaging and serological investigations to assess whether atovaquone significantly reduces tumour hypoxia in patients with non-small cell lung cancer.
Open label window of opportunity study
Patients with suspected non-small cell lung cancer (NSCLC)
- To investigate whether atovaquone reduces tumour hypoxia.
- To further investigate whether atovaquone reduces tumour hypoxia.Late SBRT toxicity (>1 month to 6 months post-surgery)
- To determine whether atovaquone results in a change in tumour perfusion.
- To determine whether serological markers of hypoxia may replace hyp-PET-CT imaging in future studies of hypoxia modification.
- To determine reproducibility of hyp-PET-CT, perfusion CT, serological tests, DWI-MRI and DCE-MRI
Open to recruitment: 05 May 2016
Planned accrual completion: 31 October 2018
Trial duration: 30 Months